Curative direct-acting antivirals for chronic hepatitis C provide a net economic benefit to Medicaid in less than 1 year. Cumulative savings to date have exceeded $15 billion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.37765/ajmc.2022.89273 | DOI Listing |
Publication Analysis
Top Keywords
chronic hepatitis
8
impact direct-acting
4
direct-acting antiviral
4
antiviral chronic
4
hepatitis health
4
health care
4
care costs
4
costs medicaid
4
medicaid economic
4
economic model
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!